The epidermal growth factor receptor (EGFR) is a growth factor receptor that induces cell differentiation and proliferation upon activation through the binding of one of its ligands. The receptor is located at the cell surface, where the binding of a ligand activates a tyrosine kinase in the intracellular region of the receptor. This tyrosine kinase phosphorylates a number of intracellular substrates that activates pathways leading to cell growth, DNA synthesis and the expression of oncogenes such as^os andyun.
Introduction
Growth factors belongs to a family of polypeptides which have been shown to stimulate proliferation and/ or differentiation in both normal and malignant cells. One of the first growth factors discovered was epidermal growth factor (EGF) [1] . Later studies have shown that this protein binds to a cell surface growth factor receptor, epidermal growth factor receptor (EGFR). Through binding to the receptor, EGF either induces cell proliferation or differentiation in mammalian cells [2] .
The binding of a ligand to the EGFR, induces conformational changes within the receptor which increases the catalytic activity of its intrinsic tyrosine kinase, resulting in autophosphorylation which is necessary for the biological activity [3, 4] .
The activated EGFR kinase phosphorylates tyrosine residues on a number of cellular substrates including phospholipase C-y, (PLC-y), mitogen-activated protein kinase (MAPK) and the ras GTPase-activating protein (GAP) [5, 6] , which leads to an increase in catalytical activity [7] .
The activated receptor/ligand complex is endocytosed and either degraded within the lysosomes [8] , or recycled to the plasma-membrane [9] . Endocytosis and degradation induces down-regulation of the growth factor induced signal.
Thus, the activity of EGFR is normally under positive, as well as negative regulation, through regulatory mechanisms and feed-back information.
Structure of EGFR
The EGFR consists of a single polypeptide chain of 1186 aminoacids, M r 170 kDaltons (kDa) [10] , and is expressed on the surface of the majority of normal cells. The receptor consists of three regions, the extracellular ligand binding region, the intracellular region with tyrosine kinase activity and a transmembrane region with a single hydrophobic anchor sequence, by which the receptor traverses the cell membrane a single time (Figure 1 ).
The extracellular aminoterminal end can be divided into four domains with domain III responsible for ligand binding. The ligands binding to EGFR are, besides EGF, transforming growth factor-a (TGF-a) [11] , amphiregulin (AR) [12] , Heparin-binding EGF-like growth factor (HB-EGF) [5] , and betacellulin (BTC) [13] . The cytoplasmic carboxy-terminal region of the EGFR is the region responsible for the tyrosine kinase activity and carboxyterminal regulatory functions. Just inside the cell membrane the juxtamembrane region is followed by the protein tyrosine kinase and autophosphorylation domains. The protein tyrosine kinase activity plays a key role in the regulation of cell proliferation and differentiation.
EGFR deletion mutations
A large number of deletions of the EGFR mRNA has been observed in a number of neoplasia, first in glioblastoma [14] , but recently also in non-small-cell lung carcinomas [15] , breast cancer [16] , paediatric gliomas, medulloblastomas, and ovarian carcinomas [17] .
These deletions are found both in the part of the mRNA that encodes the extracellular region of EGFR and in the part that encodes the intracellular region of the EGFR. A large number of these deletions are the result of genomic rearrangements, resulting in alternative splicing of the mRNA [18] .
No deletion mutants have been found in the transmembrane or the tyrosine kinase domains. The removal of the transmembrane domain would make it impossible for the receptor to be positioned across the membrane, which would abolish the interaction with the cell membrane associated substrates for the tyrosine kinase.
The loss of the tyrosine kinase domain would completely abolish the function of EGFR, and therefore not lead to ligand-induced signal transduction, even if growth factors were available. Thus, it is in the ligand binding and the regulatory domains where deletions seems to have an activating effect on signal transduction.
Deletion mutations in the extracellular domain
Three different deletions of the extracellular domain of EGFR have been observed, type I, II and III (EGFRvI, II and III).
EGFRvI is total deletion of the extracellular domain and resembles the v-erb-B oncoprotein [19, 20] . It is constitutivally active, and cannot be regulated by EGF [21, 22] . This deletion has only been observed in a single tumour cell line, a xenograft derived from a malignant human glioma [20] .
EGFRvII, found in gliomas with amplified rearranged EGFR genes [23] , contains a deletion of 83 aminoacids in domain IV of the extracellular domain. The 83 aminoacids deleted represents only 7% of the total polypeptide backbone mass of the EGFR. The deleted region is part of the cysteine-rich domain IV, lying between the ligand binding domain III and the transmembrane domain V. The EGFRvII is capable of transducing EGF stimulation of cell proliferation and invasion in vitro [23] , and it responds very similar to the wildtype EGFR (wtEGFR) to growth factors [23] . EGFRvII does not seem to have any influence on the malignant phenotype of the glioblastoma, that might rather be the result of the EGFR gene amplification. Due to the structural rigidity of domain IV by disulphide bonds the conformation of this domain might not be affected by a small deletion, thereby leaving the ligand binding domain intact.
The best described and the most common of the three mutants found in human cancer is EGFRvIII. This mutation is the result of intragene rearrangements that result in overexpression of transcripts lacking exons 2-7, which represents 801 basepairs (bp). In some cases this mutant does not arise from gene rearrangement, but rather from alternative splicing of the mRNA. The receptor lack aminoacids 6-273, which constitutes a large portion of the extracellular domain. The alternative splicing results in the insertion of a glycine residue at the deletion point, thereby replacing aminoacids 6-273, without altering the reading frame. The truncated EGFRvIII lacks domain I and II of the extracellular domain [14, 18, 24, 25] . The rearranged EGFRvIII gene is often amplified, thus resulting in tumour cells overexpressing the EGFRvIII [16, 19] . The overexpression of EGFRvIII does not exclude a possible overexpression of wtEGFR. This situation might occur when only one allele of the gene is rearranged, but both alleles are amplified, or when EGFRvIII arises from alternative splicing. EGFRvIII has been found in more than 50% of high and low grade gliomas [26] , in 5 of 32 lung carcinomas [15] , in 21 of 27 breast carcinomas [16, 17] , in 4 of 6 paediatric gliomas, in 6 of 7 medulloblastomas, and in 24 of 32 ovarian carcinomas [17] (table 1) .
Most of the studies concerning EGFRvIII expression in carcinomas have been performed using antibodies, only to determine whether or not the mutant was ex-pressed. These studies do not determine the genetic origin of the mutant, i.e., gene-rearrangement or alternative splicing, nor do they determine the influence of the EGFRvIII on the maligne phenotype of the cancer.
EGFRvIII is not capable of ligand binding as the deletion destroys the ligand-binding site and has a constitutively activated tyrosine kinase similar to EGFRvI [27, 28] . The EGFRvIII stimulates cell proliferation independently of ligand interaction [27] and enhances the tumourigenicity of transfected human glioma cells in nude mice [28] .
The tyrosine kinase of EGFRvIII is much less autophosphorylated when compared to wtEGFR [29] . The level of the constitutive activation of EGFRvIII is therefore lower than the activation level seen in ligand-activated wtEGFR. It has been shown that EGFRvIII is not internalised [29] , which couples changes in the extracellular domain with changes in the internalisation domain in the intracellular region. It appears that the conformation of the intracellular region is different in EGFRvIII when compared to ligand activated wtEGFR.
Thus, the mitogenic activity of EGFRvIII might be the result of the overrepresentation of the receptor at the cell surface rather than its constitutive active tyrosine kinase. Persistence of EGFRvIII at the cell surface prolongs and enhances its low level of activity.
Many studies have focused on the use of this mutant as a target for tumour specific antibodies. The inserted glycine residue at the splice site creates a new epitope, which is specific for EGFRvIII [26, 30] . Targeting this new epitope would circumvent problems occurring if wtEGFR antibodies were to be used, as most cells express wtEGFR. In addition, EGFRvIII is specifically found in malignancies and has not been found in normal tissues.
The current development of specific antibodies against EGFRvIII [16, 31] might result in a powerful therapy tool for highly specific and efficient delivery of antibodies coupled with radioactive isotopes, gene vectors or cytotoxins directly to the tumour cells.
Transfection studies using a SV40 based expression vector carrying the EGFRvIII cDNA in Chinese hamster ovary cells, revealed an altered subcellular location of EGFRvIII, when compared to wtEGFR [32] . EGFRvIII was found primarily in the endoplasmatic reticulum, whereas wtEGFR was expressed on the cell surface. This intracellular localisation has not been observed in human tumours, frozen sections of xenografts or other EGFRvIII transfected cell lines and might be restricted to these particular transfected cells.
Mutations in the cytoplasmic domain
Mutations in the cytoplasmic domain, have been investigated to a lesser extend than the extracellular deletions.
A study of eight glioblastomas expressing transcripts that did not encode large C-terminal, intracellular portions of the receptor, revealed that all the deletions were located in the intracellular inhibitory and Ca 2+ regulatory/internalisation domains of the EGFR [14] . No deletions were found in the tyrosine kinase domain. All deletions started at the same point, but the size of the deletions varied from 254 bases to a premature termination of the transcript, resulting in the truncation of the mRNA. Whether or not these transcripts are translated into active receptors remain to be established. The lack of regulatory and inhibitory domains could easily result in the generation of constitutively active receptors. A EGFR that is not internalised would very quickly be overexpressed on the cell surface, without the ability to be down-regulated. The loss of inhibitory domains would leave the substrate binding sites of the tyrosine kinase available for interaction with its substrates, even in an non-ligand-bound state.
EGFR ligands
Amongst the ligands that bind to the EGFR, a generalised motif containing six conserved cysteines is found, which via disulphide bonds creates three peptide loops [33] . This similar folding of the mature peptides ensures a common conformational structure.
AR, HB-EGF and BTC have, in addition to the conserved motif, extended N-termini that confers further specificity for target cells. AR and HB-EGF both possess a highly basic N-terminus that enables these growth factors to bind to heparin or heparan sulphate proteoglycans expressed on the cell surface [34, 35] . This can increase the activating potential of AR and HB-EGF by localising the growth factors on the cell surface, close to the EGFR.
All the ligands are synthesised as large membranebound, glycosylated precursors which, at least in the case of EGF and TGF-a, have been shown to possess biological activity [36] , suggesting that the growth factors might be able to activate EGFR via an auto-or juxtacrine mechanism, while they still remain bound to the membrane.
Coexpression of EGFR and one or more of its ligands might result in an autocrine loop, resulting in a constant activation of the EGFR tyrosine kinase domain, leading to uncontrolled growth.
EGFR signalling

EGFR activation
Ligand binding to the extracellular domain causes allosteric changes in the intracellular part of the receptor resulting in the activation of the intracellular tyrosine kinase. The autophosphorylation of the C-terminal end removes an alternate substrate/competitive inhibitor conformation, permitting access of cellular substrates to the tyrosine kinase domain.
EGFR is activated by a three step mechanism. The binding of any of the specific ligands to the receptor induces dimerisation of the ligand-binding receptors. The EGFR may dimerise with another EGFR, or it can form heterodimers with other members of the EGFR receptor family [37] . The dimerisation results in the autophosphorylation of five specific tyrosine (Tyr) residues (Tyr 1173, 1148, 1086, 1068, and 992) in the carboxy-terminal end of the intracellular part of EGFR, with Tyr-1173 as the major autophosphorylation site [3] . The autophosphorylation of these five tyrosines results in the formation of binding sites for the substrates of the tyrosine kinase needed for signal transduction. Generally receptor motifs containing phosphotyrosyl residues are recognised by intracellular proteins containing src homology 2 motifs, (SH2). This recognition is an important part of the signal transduction pathway. SH2-containing signal proteins that directly or indirectly interacts with the autophosphorylated EGFR include enzymes such as PLC-yl, GAP and the syp phosphotyrosine phophatase, as well as non-enzymatic adapter molecules such as the p85 subunit of phosphatidylinositol 3-kinase, the src homology and collagen (She) protein, Grb-2 [38] and Nek [4] .
Mutational analysis have shown that the removal of the autophosphorylation sites has a severe effect on substrate binding if all five sites are removed [4] . However, if only one site is altered, the other autophosphorylation sites appear to be able to compensate for the loss of one site. A progressive reduction in EGFR affinity for PLC-yl is recorded with the loss of Tyr-1173 (27%), Tyr-1173 and Tyr-1148 (65%), and Tyr-1173, Tyr-1148 and Tyr-1068 (82%) [4] .
The recognition by PLC-yl of the tyrosine kinase domain of the EGFR seems to be independent of the recognised autophosphorylation site, which explains the gradual loss of EGFR affinity for PLC-yl.
In the case of EGFRvIII, which is poorly autophosphorylated, the mutation of a single autophosphorylation site abolishes tyrosine kinase activity [29] .
EGFR inactivation
The down-regulation of EGFR is partly accomplished by internalisation of the activated EGFR, followed by degradation in the lysosomes, and partly by the desensitisation induced by phosphorylation of serine and threonine residues in the intracellular domain [39] [40] [41] .
EGFR's are normally diffusely distributed on the surface of the cell. Upon ligand binding they cluster in coated pits and are endocytosed in vesicles that ultimately fuses with lysosomes [42] . Both the receptor and the ligand are then degraded in the lysosomes. A domain in the regulatory C-terminal end of the EGFR (from aminoacids 957 to 1022), has been shown to be required for endocytosis, and the deletion of the entire tyrosine kinase domain has no influence on the endocytosis of the EGFR [8, 43] . A kinase deficient receptor generated by introducing point mutations eliminates ligand-induced endocytosis [44] . These data show that internalisation is dependent on tyrosine kinase activity in the EGFR, at least if the tyrosine kinase domain is present. This might suggest the occurrence of conformational changes in the intracellular domain upon ligand-binding, involving both the tyrosine kinase domain and the regulatory C-terminus. These conformational changes would then expose sequences in the C-terminus that dictate interaction with coated pits and subsequent internalisation. It is likely that the lack of internalisation seen in EGFRvIII is caused by the inability to adapt to the endocytotic conformation.
The phosphorylation of serine and threonine residues has been shown to desensitise the EGFR. Desensitisation refers to a reduced ability of EGFR mediated signal transduction, despite an unchanged number of receptors at the cell surface. The phosphorylation of threonine 654 and serines 1002, 1046 and 1047 has been associated with a decrease in the ability of EGF to stimulate receptor dimerisation, tyrosine kinase activity, phosphatidylinositol turnover and receptor internalisation [45] .
EGFR mediated signal transduction
Tyrosine phosphorylation is a key element in the signal transduction mediated by EGFR. The stimulation of PLC-y by the EGFR mediated tyrosine phosphorylation causes the release of Ca 2+ from intracellular compartments and the generation of diacylglycerol, the activator of protein kinase C (PKC) [46] . PKC is a serine/threonine kinase [47] that possibly is responsible for the phosphorylation of the serine/threonine residues involved in the desensitisation of EGFR.
Another protein that is activated by the EGFR tyrosine kinase domain is Ras, which leads to DNA synthesis and cell proliferation, through a pathway leading from the cell surface to the nucleus [48, 49] . This pathway involves a large number of protein factors besides Ras, including Raf, MAPK [50] , cytosolic kinases and nuclear transcription factors [51] .
The SH2 adaptor protein Grb-2 recruits the Ras GDP/GTP exchange factor, Sos, to the plasma membrane upon binding to activated EGFR. This activates the MAP kinase pathway, one of the most important membrane-to-nucleus signalling pathways in eukaryotes [52] . As constitutive activation of MAP kinase-mediated mitogenic signalling pathways elicits transformation [52] , the constitutive signalling by EGFR/EGFRvIII overexpression may have a significant influence on the acquirement of the maligne phenotype.
EGFR tyrosine kinase is also involved in the progression of cells through G] phase and into S phase. This progression is mediated by a family of protein kinases, the cyclin dependent kinases, (CDK) and their corresponding activating partners, the cyclins [53] . Progression through Gi phase requires activation of the various cyclin-CDK kinase complexes. One of the critical substrates of Gi CDKs is the retinoblastoma protein, (RB), whose phosphorylation and subsequent release of RB-bound transcription factors are required for Gi to S phase transition. The blocking of EGFR ligand binding by a monoclonal antibody has been shown to reduce Gi phase CDK activities, causing G] cell cycle arrest [54] .
The identification of the substrates for the EGFR tyrosine kinase is far from complete. Transfection studies with the cell adhesion molecule epithelial cadherin (E-cadherin), has led to the hypothesis that the tyrosine phosphorylation of a E-cadherin associated protein, P-catenin, might lead to the loss of cell-cell adhesion, resulting in a more metastatic phenotype [55] . p-Catenin might be a substrate for EGFR tyrosine kinase, thereby connecting EGFR activity and metastatic potential.
The level of E-cadherin has influence on the EGFR level in the cell. Ca 2+ mediated down-regulation of E-cadherin expression resulted in a strong up-regulation of EGFR in keratinocytes, whereas E-cadherin transfection reversed this effect [56] .
It has been shown that internalised activated EGFRs are still autophosphorylated and catalytically active [57] . If the internalised EGFR continues to trigger signal transduction pathways after internalisation, the proteins interacting with the EGFR are likely to associate with the internalised EGFRs. This implies that the signalling role of EGFR continues after internalisation, and is only down-regulated when the receptor is degraded in the lysosomes. The prolonged activation period would enhance the signal transduced into the cell by the activated EGFR.
EGFR and its role in the development of the malignant phenotype
In a large number of tumours EGFR status is altered, due to overexpression and/or mutations. Amplified EGFR signalling might induce uncontrolled cell growth and a malignant phenotype. Apart from EGFR mutations, overexpression of EGFR or its ligands, or coexpression of ligands and receptor might lead to an abnormal EGFR mediated signal transduction.
Gene amplification of the EGFR gene has been observed in a number of different tumours, and found to be present in approx. 40% of glioblastoma multiforme [58] . In an fluorescence in situ hybridisation (FISH) assay, 18 out of 29 grade 3 and 4 gliomas displayed EGFR gene amplification [59] . Overexpression of EGFR were also frequently observed in breast, bladder, cervix, kidney, and ovarian tumours [60] , as well as in lung cancer and various squamous carcinomas [61] .
Treatment with EGF of a oesophageal cancer cell line expressing E-cadherin and EGFR induced changes in the cellular morphology and phosphorylation of Pcatenin [62] .
In some colon cancer cell lines treatment with EGF, or TGF-a, caused a reduction of E-cadherin, and an increase of a 2 -integrin, carcinoembryonic antigen (CEA) and CD44 [63] . These changes might increase the metastatic potential of the cells. Hypothetically, the reduction in E-cadherin level leads to decreased cell-cell adhesion enabling initial detachment of cells from the primary tumour. The increased integrin and CEA expression might enhance attachment and spreading of cells through the extracellular matrix, while increased expression of CD44 could enable attachment of tumour cells to endothelial cells and facilitate access to the circulation.
Possible roles of EGFR in research and cancer treatment
The EGFR has been used as a prognostic marker for a number of years, as the overexpression of EGFR was correlated to a poor prognosis in a number of cancer forms, including breast cancer [61] , gliomas [64] , squamous carcinoma [65] and laryngeal cancer [66] . In other cases, e.g., non-small-cell lung cancer, there is controversy whether or not EGFR overexpression can be used as a prognostic marker [67] [68] [69] [70] [71] .
More recently the EGFR has been studied intensively as a target for monoclonal antibodies. The overexpression of EGFR in many tumours compared to normal tissue, makes it possible to use EGFR as a target for the delivery of cytotoxins or radioactive isotopes preferentially to the tumour cells, or to use EGFR as a target for gene therapy.
A number of studies have been published using EGFR specific antibodies to modulate cell growth on cell lines of various cancer forms. A EGFR-blocking monoclonal antibody has been shown to up-regulate p27 Km and to inhibit proliferation by arresting cell cycle progression in Gj, when administered to a prostatic cancer cell line [72] .
The use of EGFR-blocking antibodies has been investigated using xenografts of a squamous cell carcinoma cell line overexpressing EGFR [73] . The blocking antibodies were found uniformly localised on tumour membranes, and induced almost complete regression. In vitro studies using the same cell line and antibodies revealed that the treatment with EGFR blocking antibodies induced terminal differentiation.
Another way to inhibit EGFR activity is to prevent translation of EGFR mRNA by the use of antisense oligonucleotides. These antisense oligonucleotides can be synthesised by a oligosynthesiser as phosphothiorate oligos (S-oligos), and administered to the cells in solution, or the antisense sequence can be antisense mRNA, obtained by transfecting the antisense EGFR sequence into the relevant cell lines. The use of S-oligos specific to the EGFR ligands AR and TGFa, has been used in combination with EGFR-blocking antibodies to inhibit growth of a human colon cancer cell line which coexpresses both EGFR and its ligands [74] . These experiments showed an additive inhibitory effect when using the combination of blocking antibodies and antisense S-oligos.
The stable transfection of EGFR specific antisense mRNA constructs into a human epidermoid carcinoma cell line that overexpresses EGFR, considerably reduced the level of EGFR expressed in the cells and restored serum dependent growth [75] .
Another way to target EGFR overexpressing cells is to use the ligands as carriers of e.g. cytotoxins. A fusion protein consisting of TGFa and Pseudonomas exotoxin have been examined for cytotoxic effects on normal and tumourigenic breast cancer cells both in vitro and in vivo [76] . The toxin inhibited cell growth in vitro, as well as xenografts of breast cancer cell lines expressing EGFR in nude mice. Cell lines that did not express EGFR were unaffected by the toxin both in vitro and in vivo. This suggests that the use of cytotoxic fusion proteins might be a possible way to inhibit tumour growth of EGFR overexpressing tumours.
EGFR function can be suppressed by construction of dominant negative receptors, that inhibit EGFR signalling by heterodimerisation [77] [78] [79] . Introduction of dominant negative receptors through gene therapy might prove to be a powerful tool in the inhibition of EGFR overexpressing tumours. The transfer of the Neu ectodomain to EGFR expressing human glioma cells inhibits the transformed phenotype and can revert cell growth and proliferation to a quiescent normal level [80] . A Neu ectodomain form (N691stop) leads to inhibition of EGF-induced DNA synthesis, less efficient EGF-induced internalisation and down-regulation of EGFR activity, thereby reducing the oncogenic potential of EGFR-N691stop coexpressing fibroblasts [77] . The Neu ectodomain has a high affinity for the EGFR, which makes it a viable biologic construct for gene therapy of human glioblastoma. A similar Neu mutant, T691stop is able to form heterodimers with EGFRvIII, and might be a way to revert the mitogenic potential of this EGFR mutant [80] .
As the EGFR tyrosine kinase is necessary for signal transduction it is a good target for therapy, using tyrosine kinase inhibitors [81] . A number of studies have investigated the effect of tyrosine kinase inhibitors on cancer cell lines, in vitro [82] [83] [84] [85] [86] and in vivo [87] [88] [89] . Two classes of tyrosine kinase inhibitors are the tyrphostins [90] [91] [92] and the dianilinophtalimides (DAPH) [93, 94] . The use of a tyrphostin, RG-13022 has been shown to inhibit TGF-a-induced growth and EGFRphosphorylation in vitro [82] . DAPH has been shown to inhibit EGFR tyrosine kinase activity in vitro, and oral administration of a DAPH, CGP 54211 selectively inhibited the level of EGFR phosphorylation in a implanted human cell line in nude mice. As a consequence of the inhibited EGFR activity necrosis and inhibition of tumour growth was observed [87] . Therefore tyrosine kinase inhibitors might be a powerful therapeutic tool against EGFR overexpressing cancers.
EGFR blocking antibodies, and radiolabelled EGF or antibodies have been tested in a number of phase I trials in patients with squamous lung carcinoma [73, 95] and gliomas [72, 96, 97] . These studies have shown that the antibodies bind specifically to the tumour and that EGFR blocking antibodies can be administered safely to patients having tumours overexpressing EGFR. The doses administered were sufficient to inhibit tumour growth. A phase II study using 125 I-labeled EGFR specific antibodies has been conducted on patients with malignant astrocytoma, astrocytoma with anaplastic foci, and glioblastoma multiforme [98] . These studies revealed encouraging results with a one-year survival of 60%, and a median survival of 15.6 months for patients with glioblastoma multiforme, compared to a 50% death rate within six months when the patients are treated by surgical resection.
The antiproliferative effect of anti-EGFR monoclonal antibodies is enlarged by combination with other agents such as the cyclic adenosine monophosphate (cAMP) analogue 8-chloro-cAMP, which inhibits a cAMP dependent serine-threonine kinase which is overexpressed in many human cancers. This combination treatment delayed tumour growth significantly in mice when compared to anti-EGFR monoclonal antibody treatment alone [99] .
The generation of EGFRvIII specific monoclonal antibodies have been used to detect EGFRvIII in glioblastomas [16] . Using this approach, 8 of 11 tumours previously found EGFRvIII negative using polyvalent anti-EGFRvIII sera, were shown to be EGFRvIII positive. To be able to detect EGFRvIII in cancer cells, biopsies or xenografts must be tested, as the mutation tend to disappear when cells are cultured in vitro [25] . The reason for this phenomenon is not known.
Anti-EGFRvIII specific antibodies might prove to be superior to anti-EGFR antibodies with respect to antibody mediated treatment, as the EGFRvIII mutant is expressed exclusively on tumour cells and not on normal tissue. This could possibly reduce the toxicity after administration of isotopes or cytotoxins, coupled to specific antibodies.
Recently it has been shown that the tyrosine kinase inhibitor tyrphostin AG 1478 preferentially inhibits tyrosine kinase activity in EGFRvIII transfected cell lines, when compared to the same cell lines transfected with wtEGFR [100] . This might be used for specific targeting EGFRvIII expressing cells in cancer therapy.
Future perspectives
In a large number of tumours, EGFR is mutated or overexpressed. The EGFR gene is often amplified and deletion mutations found in cancer cells have been shown to have an constitutive active tyrosine kinase. This suggests that the EGFR plays an important role in the development of the malignant phenotype of many cancers.
A number of deletion mutants have been found, mainly in glioblastomas, but lately also in other malignancies ( Table 1 ). The development of new detection methods such as reverse transcriptase polymerase chain Figure 2 . a) Schematic presentation of the use of a EGFRvIII specific antibody as a tumour specific carrier for a radioactive isotope or a cytotoxin. The antibody will only target cells expressing EGFRvIII; b) and the radioactive isotope might then kill targeted, as well as neighbouring cells, thereby targeting radiation therapy to the tumour. Cytotoxins might get transferred from the targeted cell to neighbouring cells through intracellular transport mechanisms.
reaction (RT-PCR), and the use of EGFR-mutant specific antibodies, might prove that EGFR mutations are even more common than observed hitherto.
So far, EGFRvIII has been found in: high-and lowgrade gliomas, paediatric gliomas, medulloblastomas, breast and ovarian carcinomas as well as non-small-cell lung cancer. EGFRvIII has not been found or has not been tested in other cancer forms. The list of cancers where EGFRvIII is found will probably grow after implementation of more sensitive methods such as RT-PCR, RNase protection assays and specific monoclonal antibodies. The use of EGFR specific antibodies used for cancer therapy is promising, but serious problems can be envisioned, due to heterogeneity within the tumour, and the fact that normal cells also express EGFR. Therefore, it will be preferable to target the cancer cells with tumour specific antibodies to avoid toxicity in normal cells, when coupling an radioactive isotope, or a cytotoxin to the antibodies.
In this respect EGFRvIII is particularly interesting as the deletion in the extracellular domain creates a tumour specific epitope, that can be used as the target for monoclonal antibodies (Figure 2a ). This approach could have significant therapeutic value by coupling radioactive isotopes, or cytotoxins to the antibody. As EGFRvIII is a ligand independent constitutive active receptor the use of a blocking antibody is not possible. As the EGFRvIII constantly stimulates cell growth it is likely that the tumour cells expressing the EGFRvIII mutant are the most proliferative. The coupling of radioactive isotopes to a EGFRvIII specific monoclonal antibody would then target the fastest proliferating cells. A radioactive isotope coupled to a specific monoclonal antibody could kill neighbouring cancer cells not expressing EGFRvIII, as well as the cell expressing the antigen, thereby overcoming the problems arising from tumour heterogeneity (Figure 2b) .
The use of EGFRvIII specific antibodies and transfected cell lines expressing EGFR or EGFRvIII, could be very useful tools to investigate the role of EGFR and EGFRvIII, in the development of the malignant phenotype.
